Clinical trial · Interventional
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of response
Summary
Brief summary (as posted)
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- chemotherapy
- description
- Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 2-5 years
Secondary outcomes (1)
- measure
- Response rate
- timeFrame
- 2-5 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * cytologically or histologically verified anaplastic thyroid cancer * completed standard therapy * operated with R0 or R1 surgery * Performance Status 0-2 (if pulmonary mets PS 0-1) * normal wound healing * neutrophils \> 1,5 million/ml * platelets \> 100 million/ml * bilirubin \< 2 ULN * creatinin \< 150mikromol/L Exclusion Criteria: * PS 3-4 (if pulmonary mets 2-4) * R2 resection of primary tumor
References
Publications (0)
Data not yet available